Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 24 October 2017

Indication(s)

Aprovel is indicated in adults for the treatment of essential hypertension.

It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Cardiovascular Metabolism Knowledge Centre

Cardiovascular Metabolism Knowledge Centre

The Cardiovascular Metabolism Knowledge Centre is an information hub providing expert insight into the management of hypertension and type 2 diabetes. This Knowledge Centre contains a wealth of scientific video content offering insights and opinion from some of the leading experts in the field.

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

ESICM LIVES Highlights

ESICM LIVES Highlights

ESICM LIVES Congress 2018: Bringing you the latest news and insights from the 31st ESICM LIVES Congress, 20–24 October 2018 Paris, France.

Load more

Related Content

Journal articles

Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial.

Early studies suggest that radiofrequency-based renal denervation reduces blood pressure in patients with moderate hypertension. We investigated whether an alternative technology using endovascular ultrasound renal denervation...

Added 9 months ago

Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial.

Previous catheter-based renal denervation studies have reported variable efficacy results. We aimed to evaluate safety and blood pressure response after renal denervation or sham control in patients with uncontrolled hypertension...

Added 9 months ago

Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study

Carotid baroreflex activation lowers blood pressure and might have potential application for the treatment of resistanthypertension. We did a proof-of-principle trial with a...

Added 1 year ago

Valsartan 160 mg/Amlodipine 5 mg Combination Therapy versus Amlodipine 10 mg in Hypertensive Patients with Inadequate Response to Amlodipine 5 mg Monotherapy.

Background and objectives: When monotherapy is inadequate for blood pressure control, the next step is either to continue monotherapy in...

Added 3 years ago

Load more

View all 13133 Journal articles items
Guidelines

KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease

The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease aims to provide guidance on blood pressure management and treatment for...

Added 6 years ago

2013 ESH/ESC Guidelines for the management of arterial hypertension

The 2013 guidelines on hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) follow the guidelines jointly issued by the two societies in 2003 and 2007.

Added 5 years ago

Hypertension in adults: diagnosis and management

This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over.

Added 7 years ago

Load more

View all 1443 Guidelines items

More information

Category Value
Agency product number EMEA/H/C/000141
Orphan designation No
Date First Approved 27-08-1997
Type Medicinal product subject to medical prescription
Marketing authorisation holder Sanofi Clir SNC